1-3 of 3
Jens M. Chemnitz, MD
Close
Sort by
Journal Articles

Increased Functional T Cell Defects in Patients with low CD4 Counts after Allogeneic Hematopoietic Stem Cell Transplantation

Udo Holtick, MD PhD, Lukas P. Frenzel, MD, Shimabukuro-Vornhagen Alexander, MD, Sebastian Theurich, MD, Julia Claasen, Christof Scheid, MD, PhD, Michael von-Bergwelt-Baildon, MD PhD, Michael Hallek, MD PhD, Clemens Wendtner, MD, Jens M. Chemnitz, MD
Journal: Blood
Blood (2013) 122 (21): 4588.
https://doi.org/10.1182/blood.V122.21.4588.4588
Published: 2013
Journal Articles

CD30-Targeted Therapy with Brentuximab Vedotin Combined with Donor Lymphocyte Infusions Induce Sustained Clinical Remissions and Tumor Specific Immunity in a Series of Patients with Relapsed Hodgkin Lymphoma After Allogeneic Stem Cell Transplantation

Sebastian Theurich, MD, Joke Malcher, Kerstin Wennhold, Alexander Shimabukuro-Vornhagen, MD, Jens M. Chemnitz, MD, Holtick Udo, MD, Anke Krause, MD, Carsten Kobe, MD, Deniz Kahraman, MD, Chakupurakal Geothy, Andreas Engert, MD PhD, Scheid Christof, MD, Michael Hallek, MD PhD, Michael von Bergwelt-Baildon, MD, PhD
Journal: Blood
Blood (2012) 120 (21): 4213.
https://doi.org/10.1182/blood.V120.21.4213.4213
Published: 2012
Journal Articles

A Phase II Clinical Trial of the Anti-EGFR Antibody Cetuximab in Patients with Refractory or Relapsed Multiple Myeloma: Final Results,

Bastian von Tresckow, MD, Boris Böll, MD, Dennis A. Eichenauer, MD, Denissa Peine, Stefan Knop, MD, Mariele Goebeler, MD, Jens M. Chemnitz, MD, Michael Hallek, MD, Andreas Engert, MD, Kai Hübel, MD
Journal: Blood
Blood (2011) 118 (21): 3965.
https://doi.org/10.1182/blood.V118.21.3965.3965
Published: 2011